The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus

Clinical Immunology

Volumn 121, Issue 3, 2006, Pages 243-250

  Oates, Jim C ^a   Gilkeson, Gary S ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

3 Nitrotyrosine; Apoptosis; Autoantigens; Lipid peroxidation; Lupus; Nitric oxide; Reactive nitrogen species; Reactive oxygen species

Indexed keywords

AMINOGUANIDINE; ANTIGEN; DNA; GW 273629; IMIDAZOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; N(G) METHYLARGININE; NITRIC OXIDE; PEROXYNITRITE; PROTEIN; REACTIVE OXYGEN METABOLITE; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE;

DRUG MECHANISM; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; IC 50; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 33750942095     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2006.06.001     Document Type: Short Survey

References (78)

1. Zahrt T.C., and Deretic V. Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid. Redox Signal. 4 (2002) 141-159
2. Rahman I., Yang S.R., and Biswas S.K. Current concepts of redox signaling in the lungs. Antioxid. Redox Signal. 8 (2006) 681-689
3. Alderton W.K., Cooper C.E., and Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357 (2001) 593-615
4. Kleinert H., Pautz A., Linker K., et al. Regulation of the expression of inducible nitric oxide synthase. Eur. J. Pharmacol. 500 (2004) 255-266
5. E. Karpuzoglu, S.A. Ahmed, Estrogen regulation of nitric oxide and inducible nitric oxide synthase (iNOS) in immune cells: implications for immunity, autoimmune diseases, and apoptosis, Nitric Oxide (in press) (Electronic publication ahead of print).
6. Reilly C.M., Oates J.C., Sudian J., et al. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. Clin. Immunol. 98 (2001) 337-345
7. Lincoln J., Hoyle C.H.V., and Burnstock G. Nitric Oxide in Health and Disease (1997), Cambridge Univ. Press, New York, NY
8. Human Proteome Resource Program, NOS2A in normal tissues; [accessed May 19, 2006], Available from: http://www.hpr.se/tissue_profile.php?antibody_id=2014
9. Xia Y., and Zweier J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 6954-6958
10. Gaertner S.A., Janssen U., Ostendorf T., et al. Glomerular oxidative and antioxidative systems in experimental mesangioproliferative glomerulonephritis. J. Am. Soc. Nephrol. 13 (2002) 2930-2937
11. Abraham N.G., and Kappas A. Heme oxygenase and the cardiovascular-renal system. Free Radical Biol. Med. 39 (2005) 1-25
12. Boyd C.S., and Cadenas E. Nitric oxide and cell signaling pathways in mitochondrial-dependent apoptosis. Biol. Chem. 383 (2002) 411-423
13. Perl A., Gergely Jr. P., Nagy G., et al. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol. 25 (2004) 360-367
14. Mollace V., Muscoli C., Masini E., et al. Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol. Rev. 57 (2005) 217-252
15. Schmidt P., Youhnovski N., Daiber A., et al. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J. Biol. Chem. 278 (2003) 12813-12819
16. G-monomethyl-l-arginine. J. Exp. Med. 179 (1994) 651-660
17. Keng T., Privalle C.T., Gilkeson G.S., et al. Peroxynitrite formation and decreased catalase activity in autoimmune MRL-lpr/lpr mice. Mol. Med. 6 (2000) 779-792
18. Delgado Alves J., Mason L.J., Ames P.R., et al. Antiphospholipid antibodies are associated with enhanced oxidative stress, decreased plasma nitric oxide and paraoxonase activity in an experimental mouse model. Rheumatology (Oxford) 44 (2005) 1238-1244
19. Bremer V., Tojo A., Kimura K., et al. Role of nitric oxide in rat nephrotoxic nephritis: comparison between inducible and constitutive nitric oxide synthase. J. Am. Soc. Nephrol. 8 (1997) 1712-1721
20. Heeringa P., van Goor H., Moshage H., et al. Expression of iNOS, eNOS, and peroxynitrite-modified proteins in experimental anti-myeloperoxidase associated crescentic glomerulonephritis. Kidney Int. 53 (1998) 382-393
21. Ohse T., Ota T., Kieran N., et al. Modulation of interferon-induced genes by lipoxin analogue in anti-glomerular basement membrane nephritis. J. Am. Soc. Nephrol. 15 (2004) 919-927
22. Reilly C.M., Farrelly L.W., Viti D., et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 61 (2002) 839-846
23. Oates J.C., Ruiz P., Alexander A., et al. Effect of late modulation of nitric oxide production on murine lupus. Clin. Immunol. Immunopathol. 83 (1997) 86-92
24. Takeda Y., Takeno M., Iwasaki M., et al. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin. Exp. Immunol. 138 (2004) 237-244
25. Lui S.L., Tsang R., Wong D., et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 11 (2002) 411-418
26. Yu C.C., Yang C.W., Wu M.S., et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J. Lab. Clin. Med. 138 (2001) 69-77
27. Mishra N., Reilly C.M., Brown D.R., et al. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J. Clin. Invest. 111 (2003) 539-552
28. Gilkeson G.S., Mudgett J.S., Seldin M.F., et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J. Exp. Med. 186 (1997) 365-373
29. Zou M.H., Cohen R., and Ullrich V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium 11 (2004) 89-97
30. Zou M.H., Shi C., and Cohen R.A. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 109 (2002) 817-826
31. Casciola-Rosen L.A., Anhalt G., and Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179 (1994) 1317-1330
32. Oates J.C., and Gilkeson G.S. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J. Investig. Med. 52 (2004) 62-71
33. Singh A.K. Lupus in the Fas lane?. J. R. Coll. Physicians Lond. 29 (1995) 475-478
34. Ohmori H., Oka M., Nishikawa Y., et al. Immunogenicity of autologous IgG bearing the inflammation-associated marker 3-nitrotyrosine. Immunol. Lett. 96 (2005) 47-54
35. Habib Moinuddin S., and Ali R. Peroxynitrite modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol. Appl. Biochem. (2005)
36. Dixit K., and Ali R. Role of nitric oxide modified DNA in the etiopathogenesis of systemic lupus erythematosus. Lupus 13 (2004) 95-100
37. Njoku C.J., Patrick K.S., Ruiz Jr. P., et al. Inducible nitric oxide synthase inhibitors reduce urinary markers of systemic oxidant stress in murine proliferative lupus nephritis. J. Investig. Med. 53 (2005) 347-352
38. Furusu A., Miyazaki M., Abe K., et al. Expression of endothelial and inducible nitric oxide synthase in human glomerulonephritis. Kidney Int. 53 (1998) 1760-1768
39. Wang J.S., Tseng H.H., Shih D.F., et al. Expression of inducible nitric oxide synthase and apoptosis in human lupus nephritis. Nephron 77 (1997) 404-411
40. Oates J.C., Christensen E.F., Reilly C.M., et al. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. Proc. Assoc. Am. Physicians 111 (1999) 611-621
41. Kuhn A., Fehsel K., Lehmann P., et al. Aberrant timing in epidermal expression of inducible nitric oxide synthase after UV irradiation in cutaneous lupus erythematosus. J. Invest. Dermatol. 111 (1998) 149-153
42. Belmont H.M., Levartovsky D., Goel A., et al. Increased nitric oxide production accompanied by the up-regulation of inducible nitric oxide synthase in vascular endothelium from patients with systemic lupus erythematosus. Arthritis Rheum. 40 (1997) 1810-1816
43. Wanchu A., Khullar M., Deodhar S.D., et al. Nitric oxide synthesis is increased in patients with systemic lupus erythematosus. Rheumatol. Int. 18 (1998) 41-43
44. Gilkeson G., Cannon C., Oates J., et al. Correlation of serum measures of nitric oxide production with lupus disease activity. J. Rheumatol. 26 (1999) 318-324
45. Andersen G.N., Caidahl K., Kazzam E., et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis-findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 43 (2000) 1085-1093
46. Ho C.Y., Wong C.K., Li E.K., et al. Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 42 (2003) 117-122
47. Jungersten L., Edlund A., Petersson A.S., et al. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin. Physiol. 16 (1996) 369-379
48. Morgan P.E., Sturgess A.D., and Davies M.J. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum. 52 (2005) 2069-2079
49. Oates J.C., Levesque M.C., Hobbs M.R., et al. Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in African-Americans. J. Rheumatol. 30 (2003) 60-67
50. Hobbs M.R., Udhayakumar V., Levesque M.C., et al. A new NOS2 promoter polymorphism associated with increased nitric oxide production and protection from severe malaria in Tanzanian and Kenyan children. Lancet 360 (2002) 1468-1475
51. Xu W., Humphries S., Tomita M., et al. Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: assessment of the NOS2A gene and predisposition to infectious disease. Nitric Oxide 4 (2000) 379-383
52. Kun J.F., Mordmuller B., Perkins D.J., et al. Nitric oxide synthase 2 (G-954C), increased nitric oxide production, and protection against malaria. J. Infect. Dis. 184 (2001) 330-336
53. Habib Moinuddin S., and Ali R. Peroxynitrite-modified DNA: a better antigen for systemic lupus erythematosus anti-DNA autoantibodies. Biotechnol. Appl. Biochem. 43 (2006) 65-70
54. Khan F., and Ali R. Antibodies against nitric oxide damaged poly l-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J. Biochem. Mol. Biol. 39 (2006) 189-196
55. Huber J., Bochkov V.N., Binder B.R., et al. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid. Redox Signal. 5 (2003) 163-169
56. Fukunaga M., Makita N., Roberts L.J.d., et al. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am. J. Physiol. 264 (1993) C1619-C1624
57. Lopez L.R., Simpson D.F., Hurley B.L., et al. OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome: pathogenic implications for vascular involvement. Ann. N. Y. Acad. Sci. 1051 (2005) 313-322
58. Heery J.M., Kozak M., Stafforini D.M., et al. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J. Clin. Invest. 96 (1995) 2322-2330
59. Coles B., Bloodsworth A., Clark S.R., et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ. Res. 91 (2002) 375-381
60. Coles B., Bloodsworth A., Eiserich J.P., et al. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J. Biol. Chem. 277 (2002) 5832-5840
61. Delles C., Jacobi J., Schlaich M.P., et al. Assessment of endothelial function of the renal vasculature in human subjects. Am. J. Hypertens 15 (2002) 3-9
62. Kirchner L., Weitzdoerfer R., Hoeger H., et al. Impaired cognitive performance in neuronal nitric oxide synthase knockout mice is associated with hippocampal protein derangements. Nitric Oxide 11 (2004) 316-330
63. Yang C.W., Yu C.C., Ko Y.C., et al. Aminoguanidine reduces glomerular inducible nitric oxide synthase (iNOS) and transforming growth factor-beta 1 (TGF-β1) mRNA expression and diminishes glomerulosclerosis in NZB/W F1 mice. Clin. Exp. Immunol. 113 (1998) 258-264
64. Glaxo-Smith-Kline, Product Development Pipeline, February 2006; [accessed May 19, 2006], Available from: http://www.gsk.com/financial/product_pipeline/docs/pipeline.pdf.
65. National Library of Medicine, ClinicalTrials.gov; [accessed May 19, 2006], Available from: http://www.ClinicalTrials.gov.
66. Blasko E., Glaser C.B., Devlin J.J., et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J. Biol. Chem. 277 (2002) 295-302
67. Ichinose F., Hataishi R., Wu J.C., et al. A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in endotoxemic mice. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H2524-H2530
68. Enkhbaatar P., Murakami K., Shimoda K., et al. Inducible nitric oxide synthase dimerization inhibitor prevents cardiovascular and renal morbidity in sheep with combined burn and smoke inhalation injury. Am. J. Physiol.: Heart Circ. Physiol. 285 (2003) H2430-H2436
69. Piganelli J.D., Flores S.C., Cruz C., et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51 (2002) 347-355
70. Tse H.M., Milton M.J., and Piganelli J.D. Mechanistic analysis of the immunomodulatory effects of a catalytic antioxidant on antigen-presenting cells: implication for their use in targeting oxidation-reduction reactions in innate immunity. Free Radical Biol. Med. 36 (2004) 233-247
71. Crow J.P., Calingasan N.Y., Chen J., et al. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 58 (2005) 258-265
72. Ohmori H., and Kanayama N. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun. Rev. 4 (2005) 224-229
73. Habib S., Moinuddin, and Ali R. Acquired antigenicity of DNA after modification with peroxynitrite. Int. J. Biol. Macromol. 35 (2005) 221-225
74. Morrow J.D., and Roberts L.J. The isoprostanes: unique bioactive products of lipid peroxidation. Prog. Lipid Res. 36 (1997) 1-21
75. Frostegard J., Svenungsson E., Wu R., et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52 (2005) 192-200
76. Botti H., Trostchansky A., Batthyany C., et al. Reactivity of peroxynitrite and nitric oxide with LDL. IUBMB Life 57 (2005) 407-412
77. J.C. Oates, G.S. Gilkeson, Nitric Oxide in SLE, in: Tsokos GC, Gordon C, Smolen JS: (Eds). Systemic Lupus Erythematosus: A Companion to Rheumatology, ed. Elsevier, 2006 (in press) (ISBN: 0323044344ISBN-13: 9780323044349).
78. Southan G.J., and Szabo C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 51 (1996) 383-394